Why Lexicon Pharmaceuticals, Inc.’s (LXRX) Stock Is Down 5.06%
As of Wednesday, July 08, Lexicon Pharmaceuticals, Inc.’s LXRX share price has dipped by 5.06%, which has investors questioning if this is right time to buy.Michael Rose
Stock Evaluator: Lexicon Pharmaceuticals, Inc. (LXRX)
Lexicon Pharmaceuticals, Inc. LXRX
$2.34
-0.01
-0.21%
July 31, 2026 2:15:23 PM
EST
Volume: 1,090,911
After Hours: $120.37
0.15
|
0.12%
November 10, 2021 7:59 PM
EST
Volume: 72,713
USD
NASD | DELAYED PRICE
| SECTOR | INDUSTRY |
| Health Care | Pharmaceuticals |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company develops sotagliflozin, an orally-delivered small molecule drug for the treatment of hypertrophic cardiomyopathy, and ZYNQUISTA (sotagliflozin) for the treatment of type 1 diabetes. It also commercializes INPEFA (sotagliflozin), a once-daily oral tablet to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes, CKD, and other cardiovascular risk factors. In addition, the company develops LX9851, an orally-delivered small molecule drug candidate for the treatment of obesity and associated cardiometabolic disorders, and pilavapadin (LX9211), an orally-delivered small molecule drug candidate for the treatment of neuropathic pain. It has strategic collaboration and license agreements with Viatris Inc. and Bristol-Myers Squibb Company. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.
Commentary & Analysis
Why Lexicon Pharmaceuticals, Inc.’s (LXRX) Stock Is Up 5.46%
As of Friday, June 26, Lexicon Pharmaceuticals, Inc.’s LXRX share price has surged by 5.46%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why Lexicon Pharmaceuticals, Inc.’s (LXRX) Stock Is Up 5.38%
As of Wednesday, June 17, Lexicon Pharmaceuticals, Inc.’s LXRX share price has surged by 5.38%, which has investors questioning if this is right time to sell.Michael Rose
Why Lexicon Pharmaceuticals, Inc.’s (LXRX) Stock Is Up 6.49%
As of Thursday, June 04, Lexicon Pharmaceuticals, Inc.’s LXRX share price has surged by 6.49%, which has investors questioning if this is right time to sell.Michael Rose
Why Lexicon Pharmaceuticals, Inc.’s (LXRX) Stock Is Down 6.04%
As of Tuesday, June 02, Lexicon Pharmaceuticals, Inc.’s LXRX share price has dipped by 6.04%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Financial Summary
| Share Statistics | LXRX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $1,039.4 | $569.9 | 46% |
|
| Shares Out (Mil) | 400.2 | 44.8 | 86% |
|
| Institutional Ownership | 95.3% | 84.6% | 67% |
|
| Float (Mil) | 262.5 | 45.1 | 78% |
|
| Beta | 0.97 | 0.67 | 58% |
|
| Avg Daily Volume (000s) | 2,644 | 294 | 86% |
|
| Price Change (52-week) |
118.7% | 65.2% | 94% |
|
| Growth | LXRX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 15.7% | 6.7% | 74% |
|
| Net Income (5yr) | 3.0% | (2.0%) | 44% |
|
| EPS (5yr) | 23.4% | 14.9% | 73 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (15.0%) | (14.9%) | 52% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 5 | 5 | 5 | |
| Current EPS | ($0.050) | ($0.159) | ($0.206) | |
| Month Ago EPS | ($0.050) | ($0.159) | ($0.206) | |
| # Rev Up | 1 | 0 | 1 | |
| # Rev Down | 0 | 0 | 0 | |
| Three Months Ago EPS | ($0.055) | ($0.181) | ($0.208) | |
| Year/Year Chg | 1,567% | 14.4% | (32.4%) | |
| Financials | LXRX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $70 | $230 | 23% |
|
| Net Income (TTM) (Mil) | ($26) | ($11) | 22% |
|
| EPS (TTM) | ($0.070) | ($0.600) | 37% |
|
| Operating Cash Flow (TTM) (Mil) | ($39) | ($6) | 11% |
|
| Net Cash Flow (TTM) (Mil) | $4 | $4 | 52% |
|
| Long-Term Debt (Q1) (Mil) | $56 | $7 | 40% |
|
| Enterprise Value (Q1) (Mil) | $855 | $493 | 40% |
|
| Valuation | LXRX | Industry Median |
Percentile (All Stocks) |
|
| P/B | 4.88 | 2.89 | 78% |
|
| P/E | na | 20.6 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | LXRX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 94.1% | 65.9% | 95% |
|
| Net Margin | (37.5%) | (0.2%) | 13% |
|
| ROA | (9.2%) | (25.5%) | 26% |
|
| ROE | (16.0%) | (21.4%) | 25% |
|
| Liabilities to Assets | 24.5% | 35.5% | 16% |
|
| F-Score | 3 | 3 | 19% |
|
Passing Stock Screens
As of 7/30/2026, from a list of 60 stock screening strategies,
GURU STRATEGY
Driehaus Screen
Factors: Size, Momentum, Growth, Earnings Estimates
Classic momentum approach that seeks out stocks that are rapidly rising in price with the belief that the rising price will attract other investors.
| Performance Since Inception: | 13.5% |
| +/- S&P 500: | +6.0 |
